Activity of Decitabine in Patients with Myelodysplastic Syndrome Previously Treated with Azacitidine

BACKGROUND: Azacitidine and decitabine are two hypomethylating agents approved by the Food and Drug Administration for the treatment of patients with myelodysplastic syndrome (MDS). The efficacy of one agent post failure of the other is unknown. METHODS: Fourteen patients with MDS post azacitidine f...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Borthakur, Gautam, El Ahdab, Samih Y., Garcia-Manero, Guillermo, Ravandi, Farhad, Ferrajoli, Alessandra, Newman, Beth A, Issa, Jean-Pierre, Kantarjian, Hagop
Format: Artigo
Jezik:Inglês
Izdano: 2008
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3702160/
https://ncbi.nlm.nih.gov/pubmed/18398735
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428190701882146
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki